Drug Trial Radar · NCT03992430
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Jul 13, 2020
Primary completion
Sep 7, 2026
Study completion Sep 7, 2026
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.
Conditions
- Muscular Dystrophy, Duchenne
Interventions
EteplirsenDrug
Solution for intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of Adverse Events (AEs)Time frame: Up to Week 148
- Part 2: Change From Baseline at Week 144 in the NSAA Total Score (for Final Analysis)Time frame: Baseline, Week 144
- Part 2: Change from Baseline at Week 72 or Week 96 in NSAA Total Score (for Conditional Efficacy Interim Analysis)Time frame: Baseline, Week 72 or Week 96
Locations
59 sites in 26 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Florida
Gainesville, Florida
Rare Disease Research, LLC
Atlanta, Georgia
Hospital Universitario San Ignacio
Bogotá, Colombia
Instituto Neurologico de Colombia (INDEC)
Medellín, Colombia
Hospital Pablo Tobón Uribe
Medellín, Colombia
Brno Klinika detske neurologie
Brno, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Rigshospitalet Copenhagen University Hospital
Copenhagen, Denmark
Hopital Femme Mere Enfant
Bron, France
Hopital Armand Trousseau
Paris, France
CHRU de Strasbourg
Strasbourg, France
Charité Universitätsmedizin Berlin CVK
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
IASO Children's Hospital
Marousi, Attica, Greece
Semmelweis Egyetem Genomikai Medicina és Ritka Betegsegek Intezete
Budapest, Hungary
Royal Institute of Child Neurosciences
Ahmedabad, India
Aster RV Hospital
Bengaluru, India
Nizam's Institute of Medical Sciences
Hyderabad, India
Jaicare Hospital (A Unit of Sarvee Integra Pvt Ltd.)
Madurai, India
All India Institute of Medical Sciences
New Delhi, India
Sir Ganga Ram Hospital
New Delhi, India
Deenanath Mangeshkar Hospital & Research Centre
Pune, India
Christian Medical College
Vellore, India
Children's Health Ireland (CHI) at Temple Street
Dublin, Ireland
IRCCS Instituto Gianna Gaslini
Genova, Italy
Fondazione Policlinico Universitario A. Gemelli- IRCCS
Rome, Italy
The Specialty Hospital (TSH)/Advanced Clinical Center
Amman, Jordan
Istiklal Hosptial (IST)
Amman, Jordan
Irbid Specialty Hospital
Irbid, Jordan
Pharmaceutical Research Center/Jordan University of Science and Technology
Irbid, Jordan
Instituto de Investigaciones Clinicas para la Salud A.C
Durango, Mexico
Neurociencias Estudios Clínicos S.C.
Culiacán, Sinaloa, Mexico
Leids Universitair Medisch Centrum
Leiden, Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
New Zealand Clinical Research - Auckland
Auckland, New Zealand
Oslo Universitetssykehus HF Rikshospitalet
Oslo, Norway
Children's Department and Department for Children's Habilitation at Stavanger University Hospital
Stavanger, Norway
Klinika Neurologii Rozwojowej
Gdansk, Pomeranian Voivodeship, Poland
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.